Skip to content
value.today

Theraclone Sciences, Inc.

Total raised
$22 M
4 rounds on record
Latest round
$3 M
Apr 2015
First round on record
Mar 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Theraclone Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2015$3 MNo. 4$2 to $10 million

Theraclone Sciences, Inc.: Raise no. 4, Apr 2015

Investors in this round

12 investors had bought by the notice of May 7, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford Stocks · Executive Officer, Director
  • Kristine Swiderek · Executive Officer
  • Russ Hawkinson · Executive Officer
  • Steven Gillis · Executive Officer, Director
  • Christopher Mirabelli · Director
  • Wende Hutton · Director
  • Wendye Robbins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes the exercise price of warrants, which warrants may never be exercised.”

Signed by Russ Hawkinson, Chief Financial Officer. Source: SEC Form D, newest notice filed May 7, 2015. Read the notice at the SEC.

equity, optionsSEC
Mar 2013$6 MNo. 3$2 to $10 million

Theraclone Sciences, Inc.: Raise no. 3, Mar 2013

Investors in this round

2 investors had bought by the notice of Jul 29, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford Stocks · Executive Officer, Director
  • Eleanor Ramos · Executive Officer
  • Kristine Swiderek · Executive Officer
  • Russ Hawkinson · Executive Officer
  • Steven Gillis · Executive Officer, Director
  • Witold Cieplak · Executive Officer
  • Christopher Mirabelli · Director
  • Wende Hutton · Director
  • Wendye Robbins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the exercise price of warrants.”

Signed by Russ Hawkinson, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Jul 29, 2013. Read the notice at the SEC.

debt, optionsSEC
Aug 2011$12 MNo. 2$10 to $50 million

Theraclone Sciences, Inc.: Raise no. 2, Aug 2011

Investors in this round

13 investors had bought by the notice of Nov 23, 2011: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Russ Hawkinson · Executive Officer
  • Steven Gillis · Executive Officer, Director
  • Christopher Mirabelli · Director
  • Wende Hutton · Director
  • William Greene · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Russ Hawkinson, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 23, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$2 MNo. 1Under $2 million

Theraclone Sciences, Inc.: Raise no. 1, Mar 2010

Investors in this round

1 investor had bought by the notice of Mar 17, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock and the Common Stock issuable upon the conversion of the Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Fanning · Executive Officer, Director
  • Russ Hawkinson · Executive Officer
  • Steven Gillis · Executive Officer, Director
  • Christopher Mirabelli · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Fanning, President. Source: SEC Form D, newest notice filed Mar 17, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Theraclone Sciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2015).

    SEC Form D · May 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2015

That is all the official record says: Theraclone Sciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Theraclone Sciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Theraclone Sciences, Inc.
NameRoleNamed in
Clifford StocksExecutive officerMay 2015
Kristine SwiderekExecutive officerMay 2015
Russ HawkinsonExecutive officerMay 2015
Steven GillisExecutive officerMay 2015
Eleanor RamosExecutive officerJul 2013
Teri KollerExecutive officerJul 2013
Witold CieplakExecutive officerJul 2013
David FanningExecutive officerMar 2010
Christopher MirabelliDirectorMay 2015
Clifford StocksDirectorMay 2015
Steven GillisDirectorMay 2015
Wende HuttonDirectorMay 2015
Wendye RobbinsDirectorMay 2015
William GreeneDirectorNov 2011
David FanningDirectorMar 2010

About

Company in Seattle, United States.